Last Updated : September 8, 2023
Details
FilesGeneric Name:
dapagliflozin
Project Status:
Complete
Therapeutic Area:
Chronic kidney disease
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Non-Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
SX0749-000 - SR0749-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
It is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
| Call for patient/clinician input open | 30-Jun-22 |
|---|---|
| Call for patient/clinician input closed | 22-Aug-22 |
| Clarification: - Patient input submission received from CARP (Canadian Association of Retired Persons), and The Kidney Foundation of Canada | |
| Call for industry input open | 30-Jun-22 |
| Call for industry input closed | 22-Aug-22 |
| Clarification: - Patient input submission received from Canadian Association of Retired Persons and The Kidney Foundation of Canada | |
| Expert committee meeting (initial) | 29-Jun-23 |
| Draft recommendation posted for stakeholder feedback | 20-Jul-23 |
| End of feedback period | 03-Aug-23 |
| Final recommendation posted | 23-Aug-23 |
| CADTH review report(s) posted | 23-Aug-23 |
Files
Last Updated : September 8, 2023